The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents
Open accessAbstract
BACKGROUND: Dengue, a mosquito-borne viral disease, was designated a World Health Organization top 10 threat to global health in 2019. METHODS: We present primary efficacy data from part 1 of an ongoing phase 3 randomized trial of a tetravalent dengue vaccine candidate (TAK-003) in regions of Asia and Latin America in which the disease is endemic. Healthy children and adolescents 4 to 16 years of age were randomly assigned in a 2:1 ratio (stratified according to age category and region) to receive two doses of vaccine or placebo 3 months apart. Participants presenting with febrile illness were tested for virologically confirmed dengue by serotype-specific reverse-transcriptase polymerase chain reaction. The primary end point was overall vaccine efficacy in preventing virologically confirmed dengue caused by any dengue virus serotype. RESULTS: Of the 20,071 participants who were given at least one dose of vaccine or placebo (safety population), 19,021 (94.8%) received both injections and were included in the per-protocol analysis. The overall vaccine efficacy in the safety population was 80.9% (95% confidence interval [CI], 75.2 to 85.3; 78 cases per 13,380 [0.5 per 100 person-years] in the vaccine group vs. 199 cases per 6687 [2.5 per 100 person-years] in the placebo group). In the per-protocol analyses, vaccine efficacy was 80.2% (95% CI, 73.3 to 85.3; 61 cases of virologically confirmed dengue in the vaccine group vs. 149 cases in the placebo group), with 95.4% efficacy against dengue leading to hospitalization (95% CI, 88.4 to 98.2; 5 hospitalizations in the vaccine group vs. 53 hospitalizations in the placebo group). Planned exploratory analyses involving the 27.7% of the per-protocol population that was seronegative at baseline showed vaccine efficacy of 74.9% (95% CI, 57.0 to 85.4; 20 cases of virologically confirmed dengue in the vaccine group vs. 39 cases in the placebo group). Efficacy trends varied according to serotype. The incidence of serious adverse events was similar in the vaccine group and placebo group (3.1% and 3.8%, respectively). CONCLUSIONS: TAK-003 was efficacious against symptomatic dengue in countries in which the disease is endemic. (Funded by Takeda Vaccines; TIDES ClinicalTrials.gov number, NCT02747927.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global distribution and burden of dengue
Bhatt, S., Gething, P. W., Brady, O. J., Messina, J. P., Farlow, A. W., Moyes, C. L., Drake, J. M., Brownstein, J. S., Hoen, A. G., Sankoh, O., et al. (2013) · Nature · doi:10.1038/nature12060 · Cited by 10,037
Dengue: a continuing global threat
Guzman, M. G., Halstead, S. B., Artsob, H., Buchy, P., Farrar, J., Gubler, D. J., Hunsperger, E., Kroeger, A., Margolis, H. S., Martínez, E., et al. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2460 · Cited by 2,082
Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus
Brady, O. J., Gething, P. W., Bhatt, S., Messina, J. P., Brownstein, J. S., Hoen, A. G., Moyes, C. L., Farlow, A. W., Scott, T. W., & Hay, S. I. (2012) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001760 · Cited by 1,864
Capeding, M. R., Tran, N. H., Hadinegoro, S. R. S., Ismail, H. I. H. M., Chotpitayasunondh, T., Chua, M. N., Luong, C. Q., Rusmil, K., Wirawan, D. N., Nallusamy, R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61060-6 · Cited by 973
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
Sridhar, S., Luedtke, A., Langevin, E., Zhu, M., Bonaparte, M., Machabert, T., Savarino, S., Zambrano, B., Moureau, A., Khromava, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800820 · Cited by 783
Guzman, M. G., Alvarez, M., & Halstead, S. B. (2013) · Archives of Virology · doi:10.1007/s00705-013-1645-3 · Cited by 738
Sáez‐Llorens, X., Tricou, V., Yu, D., Rivera, L., Jimeno, J., Villarreal, A. C., Dato, E., Mazara, S., Vargas, M., Brose, M., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30632-1 · Cited by 82
Self-citationHuang, C. Y. ‐., Kinney, R. M., Livengood, J. A., Bolling, B. G., Arguello, J. J., Luy, B. E., Silengo, S. J., Boroughs, K. L., Stovall, J. L., Kalanidhi, A. P., et al. (2013) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002243 · Cited by 80
Cited by
The continued threat of emerging flaviviruses
Pierson, T. C., & Diamond, M. S. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0714-0 · Cited by 1,098
Dengue virus: epidemiology, biology, and disease aetiology
Roy, S. K., & Bhattacharjee, S. (2021) · Canadian Journal of Microbiology · doi:10.1139/cjm-2020-0572 · Cited by 440
Tricou, V., Yu, D., Reynales, H., Biswal, S., Saez-Llorens, X., Sirivichayakul, C., Lopez, P., Borja-Tabora, C., Bravo, L., Kosalaraksa, P., et al. (2024) · The Lancet Global Health · doi:10.1016/s2214-109x(23)00522-3 · Cited by 268
Self-citationBiswal, S., Borja-Tabora, C., Martinez Vargas, L., Velásquez, H., Theresa Alera, M., Sierra, V., Johana Rodriguez-Arenales, E., Yu, D., Wickramasinghe, V. P., Duarte Moreira, E., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30414-1 · Cited by 263
Self-citationModified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice
Zhang, M., Sun, J., Li, M., & Jin, X. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.07.013 · Cited by 90
Metadata
- Authors
- Biswal, S., Reynales, H., Saez-Llorens, X., Lopez, P., Borja-Tabora, C., Kosalaraksa, P., Sirivichayakul, C., Watanaveeradej, V., Rivera, L., Espinoza, F., Fernando, L., Dietze, R., Luz, K., Venâncio da Cunha, R., Jimeno, J., López-Medina, E., Borkowski, A., Brose, M., Rauscher, M., LeFevre, I., Bizjajeva, S., Bravo, L., & Wallace, D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-11-21
- Volume
- 381
- Issue
- 21
- Pages
- 2009-2019
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2987109794
- Cited by
- 405
- References
- 8
- FWCI
- 34.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. https://app.cochat.ai/papers/10.1056/nejmoa1903869
- The paper
- Biswal, S., Reynales, H., Saez-Llorens, X., Lopez, P., Borja-Tabora, C., Kosalaraksa, P., Sirivichayakul, C., Watanaveeradej, V., Rivera, L., Espinoza, F., Fernando, L., Dietze, R., Luz, K., Venâncio da Cunha, R., Jimeno, J., López-Medina, E., Borkowski, A., Brose, M., Rauscher, M., . . . Wallace, D. (2019). Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1903869
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.